Celyad Announces Third Quarter 2018 Business Update

Celyad Announces Third Quarter 2018 Business Update

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting

Celyad to Present New CYAD-01 Data from THINK Study in Relapsed/Refractory Acute Myeloid Leukemia at 2018 ASH Annual Meeting

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

Celyad Announces Exclusive Agreement for Horizon Discovery’s shRNA Platform to Develop Next-Generation Allogeneic CAR-T Therapies

Transparency notification of Victory Capital Management Inc. (Article 14 of the Law of 2 May 2007)

Transparency notification of Victory Capital Management Inc. (Article 14 of the Law of 2 May 2007)

Celyad Reports First Half 2018 Financial Results and Operational Progress

Celyad Reports First Half 2018 Financial Results and Operational Progress

Celyad Appoints Filippo Petti as Chief Financial Officer

Celyad Appoints Filippo Petti as Chief Financial Officer

Dr. Margo Roberts joins Celyad’s Board of Directors and Scientific Committee

Dr. Margo Roberts joins Celyad’s Board of Directors and Scientific Committee

Celyad Announces FDA Acceptance of IND Application for CYAD-101, a First-in-Class Non-Gene Edited Allogeneic CAR-T Candidate

Celyad Announces FDA Acceptance of IND Application for CYAD-101, a First-in-Class Non-Gene Edited Allogeneic CAR-T Candidate

Celyad announces closing of global offering

Celyad announces closing of global offering

Celyad announces pricing of $47.3 million global offering

Celyad announces pricing of $47.3 million global offering

Celyad announces launch of proposed global offering

Celyad announces launch of proposed global offering